ERBB2 and neoplasm: Five patients out of 54 with druggable alterations were included in biomarker guided trials (trials targeting BRAF V600E in two patients, trials targeting RNF43 mutation in two patients and ERBB2 mutation in one patient), and one of them was included in two trials consecutively (patient whose tumour harboured BRAF V600E and RNF43 mutation) (Fig. 2).